Please assess the completion status of the following clinical trial:

Trial Title: MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for subproject MCS-2~* Age ≧ 40 years old.~* Not being treated for BPH or LUTS with Alpha-blocker, anti-cholinergics, 5-alpha reductase inhibitors, or hormonal agents.~* PSA≦4 ng/ml within 4 weeks of V1 and no pathologically-proven prostate cancer.~* No known malignancy, except cancers without signs of recurrence for \> 5 years and no need for further anti-cancer treatment.~* AST/ALT≦3X UNL.~* creatinine≦3X UNL.~* Subjects who sign the informed consent form.~Exclusion criteria~* Subjects' LUTS are not BPH-related but are associated with such conditions as urethral stricture, prostatitis, neurogenic bladder, or pelvic treatment procedures.~* Have been treated with pelvis irradiation or pelvic surgery.~* Plan to undergo any invasive procedures within the study period, such as, prostate surgery, prostate biopsy, cystourethroscopy, pelvic surgery, laparotomy, or any procedures needing urethral catheterization.~* Participating in another investigational agent study in the past 12 weeks or are going to do so during the study period.~* Active infection or inflammation.~* Considered ineligible by the investigators.~Inclusion criteria for subproject MCS-3~* Age≧40 years old.~* The alpha-blocker dosage used should be as high as subjects can tolerate.~* No known malignancy, except cancers without signs of recurrence for \> 5 years and no need for further anti-cancer treatment.~* PSA≦10.0 ng/ml without pathologically-proven prostate cancer or other cancers. Prostate biopsy is mandatory \> 12 weeks before screening, if PSA is≧4 ng/ml to rule out prostate cancer.~* AST/ALT≦3X UNL.~* Creatinine≦3X UNL.~* Subjects who sign the informed consent form.~Exclusion criteria~* Subjects' LUTS are not BPH-related but associated with such conditions as urethral stricture, prostatitis, neurogenic bladder, or pelvic treatment procedures.~* Subjects who have been treated with pelvis irradiation or pelvic surgery.~* PSA \> 10.0 ng/ml, abnormal DRE of the prostate or any suspicion of prostate malignancy. However, those who have a negative prostate biopsy are allowed.~* Active infection or inflammation.~* Considered ineligible by the investigators.

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MCS (Type: ACTIVE_COMPARATOR): Group A: MCS 30 mg/day for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 2 capsules per day

Based on this trial design, predict the completion outcome and termination type (if applicable).